Comparative toxicity of carminomycin, rubomycin and adriamycin in mice and experience with carminomycin in spontaneous tumors of dogs.
LD50 of carminomycin, rubomycin and adriamycin were determined after their single administration of 3-, 5-, 10- and 15-fold administration once a day to 540 hybrid male mice F1 (C57Bl x CBA). Comparison of the cumulative indices for these antibiotics showed that after 3 injections they were similar. After 5 injections the cumulative properties were more pronounced for adriamycin. After 10 or 15 injections the cumulative properties were less pronounced for carminomycin. The increased sensitivity to carminomycin was determined in dogs with spontaneous tumors (in 3 with osteosarcoma and 4 with hemablastoses) comparing with healthy animals. The therapeutic effect was not evaluated because of severe toxicity. Bone marrow and gastrointestinal toxicity prevailed. The therapeutic dose for sick dogs should not exceed 0.1--0.125 mg/kg i.v., once within 3--5 days during 3 weeks.
D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy / Q000662:veterinary; D002360:Carubicin / Q000627:therapeutic use / Q000633:toxicity*; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000633:toxicity*; D004283:Dog Diseases / Q000188:drug therapy; D004285:Dogs; D004317:Doxorubicin / Q000633:toxicity*; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary
D004317:Doxorubicin; D002360:Carubicin; D003630:Daunorubicin